The Deal

AUGUST 9, 2023

Our acquisition strategy is aligned with acquiring companies with a traditional product portfolio, who have success and marquee customer relationships that we can transform with our AI platform,” SymphonyAI CEO Sanjay Dhawan told The Deal. Dhawan became CEO of SymphonyAI in 2022, replacing founder Romesh Wadhwani.

M&A 40

M&A Private Equity Retail Financial Services 40

Focus Investment Banking

APRIL 14, 2024

bakery market has shown steady historical growth, with industry revenue rising roughly 4% annum from 2004 to 2022. Jim has worked on numerous IPOs, sell-side transactions, fairness opinions, and capital raises, mainly for consumer products companies and restaurants. The $75 billion U.S. bakery industry is on an upward trajectory.

M&A 52

M&A Food Private Equity Manufacturing 52

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity. billion, Mirati for $5.8

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

Cooley M&A

JANUARY 25, 2023

Tech M&A in 2022 was a tale of two halves. billion [1] during the first half of 2022 to $189.17 billion in the second half, resulting in total 2022 volume of $720.3 billion [1] during the first half of 2022 to $189.17 billion in the second half, resulting in total 2022 volume of $720.3 trillion. [2] trillion.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 20, 2022

While 2020’s M&A landscape was characterized by whiplash volatility from choppy deal activity in the first half of the year to a surge in volume in the second half, that momentum accelerated in 2021, with no signs of slowing down heading into 2022. approved prescription cannabidiol medicine to its portfolio. driven assets.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Mergers and Inquisitions

NOVEMBER 1, 2023

They do not invest in risky biotech startups attempting to cure cancer (at least not within their traditional PE portfolios). What about when the IPO market is shut down and exits look uncertain? For more on this, please see our healthcare investment banking article. in biology. For healthcare, most of the risks are regulatory.

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

Cooley M&A

FEBRUARY 1, 2024

2023’s much-discussed downturn in mergers & acquisitions – with global M&A volume and value down 6% and 17%, respectively, from 2022 – was largely driven by the slowdown in the tech sector, with global tech M&A volumes down 51% year over year, while other sectors saw marked increases. [1] in 2022 to 5.9x

M&A 59

M&A Mergers and Acquisitions Private Equity Equities 59

Focus Investment Banking

NOVEMBER 18, 2024

This active M&A market continued for almost three years until mid-to-late 2022 when interest rates increased rapidly, making it much more expensive to buy or build new car wash locations. Alternative Solutions: I would expect to see other alternative options used by certain platforms to extend their hold periods.

Private Equity 52

Private Equity Equities IPO Valuation 52